Press Releases

Report Date Files
Portage Closes First Tranche of Private Placement 16 June 2015 Click to open
Portage's Biohaven to Begin Phase I Study in 3Q 2015 and Readying for Phase III Study Start by Q1 2016 22 April 2015 Click to open
Portage's CPP Platform Delivers a Peptide Cargo Across the Blood Brain BArrier 20 April 2015 Click to open
Portage to Present at Master Investor 2015 UK 15 April 2015 Click to open
Portage's Biohaven Announces Agreement with Inventiv Health 01 April 2015 Click to open
Portage's Biohaven Enters into Exclusive Formulation Agreement and Global License with Catalent for Lead Product 24 March 2015 Click to open
Portage's Biohaven Receives Response from FDA to its Pre-IND Meeting Request 18 December 2014 Click to open
Portage Announces Further Successful Validation of its New Proprietary Cell Permeable Peptide Platform Technology 16 December 2014 Click to open
Portage Completes Non-Brokered Private Placement for Total Proceeds of US$2,000,000 16 October 2014 Click to open
Portage Announces Additional Consultants to Expedite its PPL-003 Development Programs 06 October 2014 Click to open
Portage Announces Conversion of Its Debt into Equity 29 September 2014 Click to open
Portage Announces New Consultants for its PPL-003 Development Programs 23 September 2014 Click to open
Portage Announces Proposed Private Placement 11 September 2014 Click to open
Portage's Biohaven Granted United States Patent for Glutamate Agents in the Treatment of Mental Disorders 06 August 2014 Click to open
Portage Announces Successful Validation of its New Proprietary Cell Permeable Peptide Platform Technology 14 July 2014 Click to open